Navigation Links
Independent Data Monitoring Committee Supports Continuation of Picoplatin Phase 3 SPEAR Registration Trial in Small Cell Lung Cancer
Date:5/5/2009

ravenous picoplatin include a Phase 3 trial in SCLC and Phase 2 trials in metastatic colorectal and castration-resistant (hormone refractory) prostate cancers. The Company also is conducting a clinical trial of oral picoplatin in solid tumors. For additional information please visit http://www.poniard.com.

This release contains forward-looking statements, including statements regarding the Company's business objectives and strategic goals, drug development plans and commercialization strategy, the timing and results of clinical trials and the potential safety and efficacy of the Company's products in development. The Company's actual results may differ materially from those indicated in these forward-looking statements based on a number of factors, including risks and uncertainties associated with the current distressed economic and financial market, the Company's research and development activities; the results of pre-clinical and clinical testing; the receipt and timing of FDA and other required regulatory approvals; the market's acceptance of the Company's proposed products; the Company's anticipated operating losses, need for future capital and ability to obtain future funding; competition from third parties; the Company's ability to preserve and protect intellectual property rights; the Company's dependence on third-party manufacturers and suppliers; the Company's lack of sales and marketing experience; the Company's ability to attract and retain key personnel; changes in technology, government regulation and general market conditions; and the risks and uncertainties described in the Company's current and periodic reports filed with the Securities and Exchange Commission (SEC), including the Company's Annual Report on Form 10-K for the year ended December 31, 2008 and its Quarterly Report on Form 10-Q for the period ended March 31, 2
'/>"/>

SOURCE Poniard Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. 3SBio Inc. Announces Appointment of Ernst & Young Hua Ming as Independent Auditor
2. Concerned Shareholders of Biovail Announce - Independent Nominees for Election to Biovail Board of Directors - A Focused Commitment to Governance at Biovail
3. Spherix Recruiting New Independent Director to Regain NASDAQ Compliance
4. Independent Study Corroborates Pranas Strategy to Treat Alzheimers Disease Patients.
5. Virginia Tech engineers investigate energy independent monitoring system for bridges
6. Immtech Announces Appointment of Virchow Krause as Independent Registered Public Accounting Firm
7. French Agency AMP Appoints Dr Kamel Senouci as Director of SIVAC Initiative (Supporting Independent Immunization and Vaccine Advisory Committees)
8. Major Independent Study Underscores Utility of deCODE MI(TM) for Better Predicting Risk of Heart Attack, Informing Statin Therapy
9. ProtoKinetix Receives Independent Confirmation of AAGP Anti-Inflammatory Action
10. Independent Study Reveals SYNVISC(R) Offers Longer Knee Pain Relief and Greater Patient Satisfaction for Those Suffering from Osteoarthritis of the Knee
11. Independent Monitoring Board Recommends Completion of Accrual to Genasense(R) Phase 3 AGENDA Trial in Advanced Melanoma
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/30/2015)... N.J. , March 30, 2015  New Jersey ... innovation projects in the state of New ... next round of grant funding, announced James M. ... Jersey Health Foundation Research Grants program, an additional $500,000 ... each to fund early stage research projects that demonstrate ...
(Date:3/30/2015)... , March 30, 2015 CASI Pharmaceuticals, ... to the acquisition, development and commercialization of innovative therapeutics ... global market with a commercial focus on ... and Drug Administration (CFDA) has approved the Company,s application ... ovarian clear cell carcinoma (OCCC) patients for its proprietary ...
(Date:3/30/2015)... , March 30, 2015    Intrexon Corporation ... synthetic biology, and Merck Serono, the biopharmaceutical business ... , today announced an exclusive strategic collaboration and ... Receptor T-cell (CAR-T) cancer therapies. This collaboration advances ... therapies that modulate the immune system,s natural ability ...
(Date:3/30/2015)... 29, 2015 A two-day workshop on ... and plenary talks by four leading photonics researchers are ... Optoelectronics next month in Prague, Czech Republic. The ... conferences alongside a two-day exhibition. Sponsored by SPIE, ... event will run 13-16 April in the Clarion Congress ...
Breaking Biology Technology:New Jersey Health Foundation Announces An Additional $1 Million To Fund Innovation and Research Grants in New Jersey 2CASI Pharmaceuticals Receives Approval From CFDA For Phase 2 Clinical Trial In China With ENMD-2076 For Ovarian Clear Cell Carcinoma 2CASI Pharmaceuticals Receives Approval From CFDA For Phase 2 Clinical Trial In China With ENMD-2076 For Ovarian Clear Cell Carcinoma 3CASI Pharmaceuticals Receives Approval From CFDA For Phase 2 Clinical Trial In China With ENMD-2076 For Ovarian Clear Cell Carcinoma 4CASI Pharmaceuticals Receives Approval From CFDA For Phase 2 Clinical Trial In China With ENMD-2076 For Ovarian Clear Cell Carcinoma 5Intrexon and Merck Serono Announce Agreement for the Development and Commercialization of CAR-T Therapy 2Intrexon and Merck Serono Announce Agreement for the Development and Commercialization of CAR-T Therapy 3Intrexon and Merck Serono Announce Agreement for the Development and Commercialization of CAR-T Therapy 4Laser Energy Advances Among Reports Set for SPIE Optics + Optoelectronics 2Laser Energy Advances Among Reports Set for SPIE Optics + Optoelectronics 3
... pattern has led materials scientists at the National Institute ... Solid State Physics in Russia to an unexpected findingthe ... used in data storage. Their recently reported findings* may ... of future ultra-high density data storage devices. The ...
... 1 Biocept, Inc. ("Biocept"), an emerging leader in biotechnology, announced ... as Directors. , , "We are pleased to welcome ... to us as we move into our next stage of development," ... Ms. Wilson has been a principal of Wilson Boyles and Company, ...
... Inc., a subsidiary of Eisai Corporation of North America, ... to express and develop therapeutic monoclonal antibodies for the ... disease. , , Under the terms of the ... (SEP(TM)) technology and its expertise to produce and develop ...
Cached Biology Technology:Unexpectedly long-range effects in advanced magnetic devices 2Biocept, Inc. Announces Two New Director Appointments 2Morphotek(R), Inc. Announces a Research Collaboration Agreement with Synageva BioPharma Corporation to Develop Potential Treatments for Cancer and Infectious Disease 2Morphotek(R), Inc. Announces a Research Collaboration Agreement with Synageva BioPharma Corporation to Develop Potential Treatments for Cancer and Infectious Disease 3
(Date:3/12/2015)... , March 12, 2015 ... standardized identity and access management (IAM) solution for ... schedule. With Beta System,s new IAM package, customers ... practices gleaned from multiple IAM implementations across different ... software as well as any necessary services and ...
(Date:3/10/2015)... 2015  Continuing its 167-year history of offering the ... The Eye Scanning Password Authenticator , a device ... secure websites or sensitive data. Employing the ... borders, the device has a small camera that scans ... iris, converting them into an encrypted ID that cannot ...
(Date:3/5/2015)... PAULO , March 5, 2015 In ... 41 percent of companies already using these solutions and 42 ... 2015. Of the latter, approximately 25 percent of the companies ... While the majority of companies in the region ... anticipated that the hybrid model will command significant attention in ...
Breaking Biology News(10 mins):Beta Systems Fast Forward IAM Available Now: a Standardized IAM Package at a Fixed Price 2Hammacher Schlemmer Introduces The Eye Scanning Password Authenticator 2Two of Every Three Brazilian Companies will have Invested in Cloud by 2015, Finds Frost & Sullivan 2Two of Every Three Brazilian Companies will have Invested in Cloud by 2015, Finds Frost & Sullivan 3Two of Every Three Brazilian Companies will have Invested in Cloud by 2015, Finds Frost & Sullivan 4
... Chicago, IL The American Society of Pediatric Otolaryngology (ASPO) ... field of pediatric otolaryngology during their annual meeting, April ... awards will be presented during a banquet reception on ... & Towers. Two prestigious groups of awards will ...
... , Hamilton, ON (April 24, 2011) An over-the-counter ... antibiotic used to treat bacterial infections, could one day ... Researchers at McMaster University have discovered this ... a frequent complication of those with cystic fibrosis. Cystic ...
... RICHLAND, Wash. -- Atmospheric scientists trying to pin down ... warm the earth have found that it depends on ... will help researchers improve how they portray clouds in ... scattered by clouds the reason why beachgoers can ...
Cached Biology News:Combination therapy provides hope for cure of dangerous infections of cystic fibrosis patients 2Effect of cloud-scattered sunlight on earth's energy balance depends on wavelength of light 2Effect of cloud-scattered sunlight on earth's energy balance depends on wavelength of light 3Effect of cloud-scattered sunlight on earth's energy balance depends on wavelength of light 4
... and high speed homogeneous assay for the ... for screening of inhibitors in a high-throughput ... on a fluorescence superquenching technology that does ... universal platform provides flexibility for assaying any ...
... The HDA-GT12 Genetic Analyzer is ... multiple applications in one instrument platform. It ... in one step, thus significantly improving the ... to high-throughput laboratories . Benefits of ...
...
...
Biology Products: